Price
No data yet.
Social Signal Score
Analyst Ratings
15 analystsRevenue
$630.90M+1178.65%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Brian J. Blaser
- Sector
- Healthcare
- Industry
- Medical - Specialties
- Employees
- 6,500
- Beta
- 0.68
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -0.11
Financials
Revenue
$630.90M+1178.7%Net Income
$-92.90MEBITDA
$-26.50M-462.4%Free Cash Flow
$-136.10MEPS (diluted)
$-1.36Shares Outstanding (diluted)
68.30M+109.0%Operating Expenses
$238.40MCash & Debt
$123.40MReturn of Capital
$0.00Revenue by Segment (annual)
$483.30MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.73B | $-1.13B | $-16.69 |
| 2024 | $2.78B | $-2.05B | $-30.54 |
| 2023 | $3.00B | $-10.10M | $-0.15 |
| 2022 | $3.27B | $548.70M | $9.66 |
| 2021 | $1.70B | $704.20M | $16.74 |
| 2020 | $1.66B | $810.29M | $19.24 |
| 2019 | $534.89M | $72.92M | $1.78 |
| 2018 | $522.28M | $74.18M | $1.74 |
| 2017 | $277.74M | $-8.16M | $-0.24 |
| 2016 | $191.60M | $-13.81M | $-0.42 |
| 2015 | $196.13M | $-6.08M | $-0.18 |
| 2014 | $182.62M | $-7.07M | $-0.21 |
| 2013 | $175.41M | $7.39M | $0.22 |
| 2012 | $155.74M | $4.99M | $0.15 |
Valuation
QDELhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (6)
- Newsprnewswire.com·12d ago·Neutral
Early Intervention Aids Emergency Medicine Teams in Identifying and Personalizing Sepsis Treatment SAN DIEGO, Sept. 24, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, is proud to share episode 61 of its Science Bytes podcast, highlighting key insights about lowering sepsis rates in the emergency room.
View source ↗ - Newsprnewswire.com·40d ago·Neutral
Faster Answers, Better Decisions: ADLM 2026 Highlights SAN DIEGO, Aug. 27, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a leading global provider of diagnostic solutions, has released episode 60 of its Science Bytes podcast, featuring highlights from the 2026 Association for Diagnostics and Laboratory Medicine (ADLM) Annual Conference. Hosted by Stephanie Kleewein, the special episode showcases three presentations addressing some of healthcare's most pressing challenges: deliveri…
View source ↗ - Newszacks.com·49d ago·Neutral
QDEL's 2026 Outlook Cut Deepens China and Respiratory Risk Concerns QuidelOrtho's 2026 outlook cut highlights deeper China and respiratory risks, while cash use and rising debt add pressure despite resilient core growth.
View source ↗ - Newszacks.com·49d ago·Neutral
Is QDEL Worth Buying as China Risks Clash With Resilient Core Growth? QuidelOrtho's resilient core growth and $50 million cost plan offer support, but China weakness, cash use and heavy debt keep the near-term case cautious.
View source ↗ - Newszacks.com·49d ago·Positive
QDEL Rallies 31.7% in Three Months: Can the Stock Keep Climbing Higher? QuidelOrtho's 31.7% three-month rally meets resilient core growth and cost savings, but China weakness, lower guidance and high debt cloud further gains.
View source ↗ - Newszacks.com·56d ago·Neutral
QDEL Q2 Earnings & Revenues Beat Estimates, 2026 Guidance Lowered QuidelOrtho beats Q2 earnings and revenue estimates, but cuts its 2026 outlook on persistent China weakness and a softer respiratory testing environment.
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $0.20 per share
Typical surprise +17.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$0.13 vs $-0.05beat
- Tue, May 5$-0.04 vs $0.37miss
- Wed, Feb 11$0.46 vs $0.43beat
- Wed, Nov 5$0.80 vs $0.51beat
- Tue, Aug 5$0.12 vs $0.00beat
- Wed, May 7$0.74 vs $0.58beat
Estimates and results for QDEL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by QDEL officers and directors.
No open-market trades in the recent filings. All 100 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
100 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Daniel Goldmanhouse · NY10 · disclosed Aug 13, 2023 (32d later)Sell$1,001 - $15,000
- Tom Malinowskihouse · NJ07 · disclosed Jun 23, 2021 (43d later)Buy$15,001 - $50,000
- Tom Malinowskihouse · NJ07 · disclosed Jun 12, 2021 (46d later)Sell$1,001 - $15,000
- Tom Malinowskihouse · NJ07 · disclosed Apr 10, 2021 (38d later)Sell$15,001 - $50,000
- Tom Malinowskihouse · NJ07 · disclosed Apr 10, 2021 (27d later)Sell$1,001 - $15,000
- Tom Malinowskihouse · NJ07 · disclosed Mar 6, 2021 (11d later)Sell$15,001 - $50,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Dec 15, 2020 (32d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Dec 9, 2020 (28d later)Sell$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Aug 19, 2020 (20d later)Sell$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Aug 19, 2020 (37d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Aug 10, 2020 (33d later)Sell$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Jun 16, 2020 (26d later)Sell$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Apr 16, 2020 (37d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Apr 11, 2020 (40d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.